#Germany #Grünenthal #Uli Brödl #Chief Scientific Officer #Aachen

Grünenthal's Strategic Leadership Move: Prof. Dr. Uli Brödl Takes the Helm as Chief Scientific Officer

Grünenthal, a leading company in pain management, has announced a pivotal addition to its executive team. Starting February 1, 2025, Prof. Dr. Uli Brödl will take on the role of Chief Scientific Officer (CSO) and join the Corporate Executive Board. His extensive background in the pharmaceutical industry, where he honed his expertise for over 15 years, positions him well to advance Grünenthal's mission of enhancing the quality of life for patients in need.

Before joining Grünenthal, Brödl served at Boehringer Ingelheim as the Corporate Senior Vice President and Head of Global Clinical Development Operations. He was responsible for comprehensive clinical development activities across various therapeutic areas, overseeing critical operations to ensure drugs reached those who need them most. Brödl's efforts led to the successful development of notable medications, such as Empagliflozin, which treats diabetes and showcases his capability in bringing innovative health solutions to the marketplace.

Brödl’s previous experiences also include leading Boehringer Ingelheim's Canadian medical organization, where he gained significant market exposure. Furthermore, he has a commendable track record of founding the BI Canada Incubator, an innovation lab that enabled the development of creative healthcare solutions.

A graduate of Ludwig-Maximilians University in Munich, Brödl is not only a trained Medical Doctor but also a certified internist and endocrinologist. His involvement in academia as an Adjunct Professor of Internal Medicine displays his profound commitment to both education and practical application of medical science.

Upon his appointment, Brödl expressed enthusiasm for joining Grünenthal, citing the company's focus on improving the lives of underserved patients with pain. He highlighted his eagerness to step into the role, stating, "I look forward to joining the team and further driving Grünenthal's innovation pipeline."

Gabriel Baertschi, CEO of Grünenthal, welcomed Brödl's arrival, noting, "With Uli, we have been able to attract an excellent leader. His extensive experience in R&D and commercial functions combined with his drive to bring innovative medicines to patients will help us propel our vision of a world free of pain."

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. With a science-based approach, the company has a long-standing reputation for developing innovative treatments and technologies. Headquartered in Aachen, Germany, Grünenthal operates affiliates across 27 countries in Europe, Latin America, and the United States, with its products reaching nearly 100 nations. In 2023, Grünenthal reported revenues of €1.8 billion and employed around 4,400 people.

As the new CSO, Prof. Dr. Uli Brödl's leadership is highly anticipated, as he will play a crucial role in driving forward the company's objectives and innovation in the pharmaceutical sector. Grünenthal’s emphasis on directed research and solutions aims to fulfill its vision of not just alleviating pain but enhancing life quality globally.

Conclusion

With his impressive credentials and vision, Prof. Dr. Uli Brödl's role as CSO is expected to catalyze Grünenthal's ongoing commitment to transforming pain management and developing groundbreaking health solutions even further. As the company strives to pioneer advancements in pharmaceutical care, Brödl's leadership will be instrumental in shaping its impact on patient lives and healthcare worldwide.